Skin Cancer, Acne, Skin Injury | Dermatology News, Treatment …
网页By Alan P. Lyss, MD. Factors preventing more widespread use of biosimilars in oncology include the cost and complexity of biosimilar development, oncologists’ lack of knowledge about biosimilars, and the fact that interactions between payers, manufacturers, and pharmacy benefit managers can sometimes drive up the cost of biosimilars.
Acne Treatment Strategies Should Be Personalized, Target …
网页1 天前 · October 11, 2024. Targeting the cutaneous microbiome may enhance acne treatment strategies. Future treatments for acne vulgaris should be personalized and modulate the cutaneous microbiome, according to study results published in the Journal of the European Academy of Dermatology and Venereology. Researchers conducted a systematic review to ...
AAD Issues New Guidelines for Clinical Management of Acne …
网页2024年3月22日 · The American Academy of Dermatology (AAD) has issued updated guidelines for the clinical management of patients with acne vulgaris, which have been published in the Journal of the American Academy of Dermatology.. Systematic reviews to evaluate the effectiveness and safety of acne treatments approved by the United States Food and Drug Administration (FDA) were performed from May 2021 to ...
Update on Efficacy of Treatments for Cutaneous Candidiasis
网页November 20, 2019. The only commercially available oral therapy with evidence-based support for systemic efficacy in cutaneous candidiasis is fluconazole, according to a review of topical and systemic treatments. In an article published in the European Academy of Dermatology and Venereology, the authors evaluated findings on 19 systemic and ...
Treatment of Moderate to Severe Atopic Dermatitis: Highlights …
网页From March 17 to 21, 2023, dermatologists gathered for the American Academy of Dermatology (AAD) Annual Meeting, where they discussed the latest research on the treatment and management of a range of inflammatory skin diseases and other conditions. In this article, Emma Guttman-Yassky, MD, PhD, discusses the most exciting research on the treatment of moderate to severe atopic dermatitis ...
Systemic Treatments for Atopic Dermatitis: Which is Most Effective?
网页2024年9月10日 · Dupilumab was more effective when compared with methotrexate (MTX) for the treatment of patients with atopic dermatitis (AD), and cyclosporin (CyA) was most effective in those with very severe disease, according to study findings published in the British Journal of Dermatology.. Researchers conducted a prospective observational cohort study to compare the real-world clinical effectiveness and ...
Low-Dose Isotretinoin Effectively Reduces Rosacea Lesions and …
网页3 天之前 · Low-dose isotretinoin (LDI) is an effective treatment for moderate to severe or recalcitrant rosacea with good tolerability and safety, according to study results published in the Journal of the European Academy of Dermatology & Venereology.. Researchers conducted a systematic review and meta-analysis by searching 3 databases from inception to May 9, 2023.
Long-Term Dupilumab Is Safe, Effective for Atopic Dermatitis for …
网页2024年8月23日 · Included in the safety analysis were 2677 patients, of whom 60.2% were men. Mean (SD) patient age was 39.2 (13.4) years. The majority (82.4%) of patients continued treatment with dupilumab for at least 52 weeks and 12.5% continued treatment up to week 260 (5 years). Approximately half (48.4%) of patients completed both treatment and an end-of-study visit.
Lebrikizumab Shows Similar Efficacy to Dupilumab for Atopic …
网页2024年9月5日 · Lebrikizumab shows comparable efficacy to dupilumab in adults with atopic dermatitis with some differences in binary outcome measures, according to study results published in JAMA Dermatology.. To compare the effectiveness and safety of systemic immunomodulatory treatments for atopic dermatitis, including the recently approved lebrikizumab, a systematic review and network meta-analysis were ...
Long-Term Efficacy for Lebrikizumab Identified in Moderate, …
网页2 天之前 · October 10, 2024. Lebrikizumab has long-term efficacy for treatment of moderate-to-severe atopic dermatitis. HealthDay News — For patients with moderate-to-severe atopic dermatitis (AD), lebrikizumab has long-term efficacy, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from ...